期刊文献+

HPLC-MS/MS法测定人血浆中奥昔布宁和去乙基奥昔布宁的质量浓度 被引量:1

HPLC-MS/MS determination of oxybutynin and N-desethyloxybutynin concentration in human plasma
下载PDF
导出
摘要 目的建立HPLC-MS/MS法测定人血浆中奥昔布宁和去乙基奥昔布宁的质量浓度。方法选用Waters-At-lantis dC18色谱柱,以0.01%甲酸溶液-乙腈为流动相进行梯度洗脱,采用正离子多反应监测方式测定样品质量浓度。用于定量分析的离子对分别为m/z 358.2→142.2(奥昔布宁),m/z330.2→96.2(去乙基奥昔布宁),m/z268.2→152.2(奥昔布宁D10),m/z335.2→101.2(去乙基奥昔布宁D5)。结果血浆样品中,奥昔布宁在0.05~25ng.mL-1线性关系良好(r=0.996 5),最低定量浓度为0.05ng.mL-1;去乙基奥昔布宁在0.05~25ng.mL-1线性关系良好(r=0.998 5),最低定量浓度为0.05ng.mL-1。两者日内与日间RSD均<15%,提取回收率>75%,且稳定性均较好。结论本方法简便快速、灵敏准确、特异性强,适用于奥昔布宁和去乙基奥昔布宁的体内药物动力学研究。 Objective To establish a high performance liquid chromatography-mass spectrometry method for the determination of oxybutynin and N-desethyloxybutynin in human plasma.Methods Waters-Atlantis dC18 column was used with 0.01% formic acid solution-acetonitrile as the mobile phase in gradient elution.The multiple reaction monitor with positive mode was used.The transitions of + m/z 358.2→142.2(oxybutynin),+ m/z 330.2→96.2(N-desethyloxybutynin),m/z 268.2→152.2(oxybutynin-D10)and + m/z 335.2→101.2(N-desethyloxybutynin-D5) were used for the quantitative analysis.Results The calibration curve for oxybutynin was linear at 0.05-25 ng·mL-1(r=0.996 5),and the minimum quantitative concentration was 0.05 ng·mL-1.The calibration curve for N-desethyloxybutynin was linear at 0.05-25 ng·mL-1(r=0.998 5),and the minimum quantitative concentration was 0.05 ng·mL-1.The inter-day and intra-day precisions were less than 15%,the average recovery was above 75%.Conclusion The method is simple,rapid,sensitive,and accurate for the pharmacokinetic study of oxybutynin and N-desethyloxybutynin in human body.
作者 刘洋 郝光涛
出处 《中南药学》 CAS 2012年第2期106-109,共4页 Central South Pharmacy
关键词 高效液相色谱-质谱联用法 奥昔布宁 去乙基奥昔布宁 药物动力学 high performance liquid chromatography-mass spectrometry oxybutynin N-desethyloxybutynin pharmacokinetics
  • 相关文献

参考文献8

二级参考文献37

  • 1崔春英,杨淑先,刘英,席德荣.抗生素国家标准品的协作标定[J].中国药事,2004,18(7):443-444. 被引量:5
  • 2黄圣凯,韩可勤.生物等效性评价的几种统计方法[J].中国临床药理学杂志,1993,9(1):43-46. 被引量:125
  • 3.中国药典[S].2000年版.二部[M].,.附录XIXB.
  • 4Patrick KS, Markowitz JS, Jarvi EJ, et al. Gas chromatographicmass spectrometric analysis of plamaa oxybutynin using a deuterated internal standard[J]. J of Chromatography ( Bionmedical Application), 1989, 87:91-98.
  • 5Eeva Lukkari, Kari Aranko, Auni Juhakoski, et al. Effect of Time Interval between Food and Drug Ingestion on the Absorption of Oxybutynin from a Controlled-release Tablet[J]. Pharmacology &amp; Toxlcology .1997,81:31
  • 6Appell RA, Sand P, Dmochowski R et al: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study[J]. Mayo Clin Proc 2001,76:358
  • 7Noronha-Blob L and Kachur. Enantiomers of oxybutynin:In vitro pharmacological characterization at M1,M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contration,mydriasis and salivary secretion in guinea pigs[J]. Pharmacol Exp. Ther.1
  • 8Fredericks CM, Anderson GF &amp; Kreulen DL. A Study of the Anticholinergic and Antispasmodic Activity of Oxybutynin (Ditropan(R)) on Rabbit Detrusor[J]. Invest Urol 1975,12:317
  • 9Z. Lukkari, T.Hakonen, P. J.Neuvonen, et al. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids [J]. Clin Pharmacol 1998,53:351
  • 10Ouslander JG, Blaustein J, Connor A et al.Pharmacokinetics and clinical effects of oxybutynin in geriatric patients[J]. Urol 1988,140:47

共引文献608

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部